Pfizer, J&J Prep for Patent Cliff Amid Mixed Results

**Pfizer (NYSE: PFE) and Johnson & Johnson (NYSE: JNJ) are facing significant patent cliffs, prompting an evaluation of their preparedness for the loss of exclusivity on key drugs. Recent financial results indicate differing levels of success in transitioning to new revenue streams, with J&J demonstrating more robust operational growth in its Innovative Medicine segment compared to Pfizer's more modest underlying performance.**

Pfizer's revenue excluding COVID-19 products saw 5% operational growth in fiscal Q2 2026, with launched and acquired products contributing $3.2 billion and growing 18% operationally. Key drivers included Padcev, which increased revenue by 23% to $667 million, and the Vyndaqel family, which grew 8% operationally. Lorbrena also saw a 37% operational increase. The company is also implementing significant cost-reduction programs, expecting approximately $9.7 billion in net savings through 2029.

Johnson & Johnson reported 7.8% growth in Innovative Medicine sales, reaching $16.38 billion, or 6.8% operationally, despite a significant impact from Stelara sales decline. Tremfya sales rose 72.5% to approximately $2 billion, helping to offset Stelara's 55% revenue drop. The company raised its 2026 sales guidance to a midpoint of $101.1 billion and its adjusted EPS midpoint by $0.13 to $11.68. J&J's MedTech business offers additional diversification not present in Pfizer's portfolio.

Despite these efforts, Pfizer's reported revenue rose only 3% to $15.03 billion, with operational growth at 1%. The company also recorded a GAAP net loss of $248 million, partially due to $4.3 billion in non-cash intangible-asset impairments.